ErSO is an orally bioavailable activator of the anticipatory unfolded protein response (a-UPR). ErSO acts through ERα to elicit strong and sustained cytotoxic activation of the a-UPR. Moreover, ErSO hyperactivates the ERα-dependent a-UPR in ERα+ cancer cells leading to eradication of ERα+ breast tumors in multiple mouse models. The inactive (S)-enantiomer (Axon 3704)  is available as negative control. Also availble is ErSO-DFP as Axon 4332.

KEYWORDS: ErSO | Supplier | a-UPR activator | CAS [2407860-35-7] | Unfolded Protein Response (Non Selective) | Estrogen (ER) | Ligand | Receptors | Metastatic estrogen receptor α (ERα)-positive breast cancer | Breast tumor | Src kinase | UPR